Marengo Therapeutics to Unveil Late-breaking Clinical Data on Invikafusp at ESMO 2025 Marengo Therapeutics will present crucial Phase 2 clinical data on invikafusp, targeting resistant tumors, at ESMO 2025, showcasing innovative immunotherapy.

Marengo Therapeutics to Unveil Late-breaking Clinical Data on Invikafusp at ESMO 2025 #United_States #Cambridge #Immunotherapy #Marengo_Therapeutics #Invikafusp

Marengo Initiated Phase 2 Trial of Invikafusp Alfa for PD-1 Resistant Tumors, Expands to Europe - OncoDaily Marengo Initiated Phase 2 Trial of Invikafusp Alfa for PD-1 Resistant Tumors, Expands to Europe / cancer, ESMO Immuno-Oncology Congress, Invikafusp, Ke Liu,

Marengo Initiated Phase 2 Trial of Invikafusp Alfa for PD-1 Resistant Tumors, Expands to Europe

oncodaily.com/insight/210727

#Cancer #ESMO #ImmunoOncologyCongress #Invikafusp #Marengo #Therapeutics #OncoDaily #Oncology #Medicine #SITCAnnualMeeting #STARt001 #ClinicalTrial #Health #TcellActivation